Rituximab Therapy for Patients on Kidney Transplant Waiting List With Positive Donor Specific Crossmatch to Living Donor
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
Primary Objectives:
- Conversion of a positive donor specific cross-match to a living donor to a negative
cross-match thereby allowing successful renal transplantation.
- Transplant success or failure following the desensitization protocol.
- Determination of the effect of rituximab on the kinetics of donor specific antibodies
(DSA).
- Determination of the effect of rituximab on the kinetics of B-cell subpopulations in
peripheral blood and/or secondary lymphoid organs (lymph node biopsies at time of
transplant, if available) in both responders and non-responders using flow cytometry
and/or immunohistochemistry.
Secondary Objectives:
-Decrease in incidence of humoral rejection to less than 50 % at 1 year.